Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenue	$ 970	$ 84,866	$ 133,034	$ 91,054
Operating expenses:
Research and development	50,723	57,913	172,347	158,680
General and administrative	16,760	16,645	50,351	44,895
Total operating expenses	67,483	74,558	222,698	203,575
Income (loss) from operations	(66,513)	10,308	(89,664)	(112,521)
Other income (expense):
Interest income	6,743	8,522	20,429	22,912
Other expense, net	(66)	(15)	(194)	(253)
Total other income, net	6,677	8,507	20,235	22,659
Income (loss) before income taxes	(59,836)	18,815	(69,429)	(89,862)
Benefit from income taxes	(835)	(3,092)	(5,075)	(10,310)
Net Income (Loss)	$ (59,001)	$ 21,907	$ (64,354)	$ (79,552)
Basic (in dollars per share)	$ (1.10)	$ 0.41	$ (1.20)	$ (1.50)
Diluted (in dollars per share)	$ (1.10)	$ 0.38	$ (1.20)	$ (1.50)
Weighted-average ordinary shares outstanding used in per share calculations- basic (in shares)	53,790	53,559	53,757	53,064
Weighted-average ordinary shares outstanding used in per share calculations- diluted (in shares)	53,790	58,004	53,757	53,064
Collaboration revenue
Total revenue	$ 970	$ 84,866	$ 132,984	$ 91,004
Revenue from license and intellectual property
Total revenue	$ 0	$ 0	$ 50	$ 50

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.